Major reforms to Canada’s Patent Act are coming as the Canadian Parliament moves one step closer to ratifying the Comprehensive Economic and Trade Agreement (CETA). On March 7, 2017, Bill C-30 (the Act intended to implement CETA into Canadian law)
March 27, 2017
The Court of Appeal dismissed Teva’s appeal and addressed the role of inventors’ evidence in proving sound prediction and the use of trial-and-error testing to support sufficiency of disclosure.
March 24, 2017
Budget 2017 was tabled today by the Liberal government. While Budget 2016 contained many significant tax changes, Budget 2017 does not.
March 23, 2017
Welcome to the fifth edition of Global Asset Management Quarterly.
The Alberta government recently announced it would review Alberta’s workplace laws, including the Labour Relations Code and the Employment Standards Code.
March 22, 2017
The Competition Bureau recently cleared the proposed acquisition of Canexus Corporation by Chemtrade Logistics Income Fund despite concluding that the transaction was likely to result in a substantial lessening or prevention of competition.
On March 13, 2017, Apotex filed for leave to appeal the Federal Court of Appeal’s (FCA) decision addressing validity and infringement of AstraZeneca’s Canadian Patent No. 1,292,693 (the 693 Patent) (reported here) with the Supreme Court of Canada (SCC).
Health Canada has released for consultation the Draft Guidance Document – Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs.
Alberta recently announced that for the 2018 compliance year under the Specified Gas Emitters Regulation (SGER) it will limit the use of carbon credits to 30% of a regulated entity's compliance obligations.
Plaintiffs in follow-on competition law class actions routinely seek information from Canada’s Competition Bureau (Bureau) in aid of their actions.
March 21, 2017
Try searching our global site instead